Autologous Stem Cell Transplantation in Acute Myocardial Infarction
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00199823|
Recruitment Status : Completed
First Posted : September 20, 2005
Last Update Posted : July 6, 2011
Intracoronary transplantation of different cell populations have been used in acute myocardial infarction (AMI) with promising results. The primary objective of the ASTAMI study is to test whether intracoronary transplantation of autologous mononuclear bone marrow cells (mBMC) improve left ventricular ejection fraction (LVEF) after anterior wall AMI.
The ASTAMI study is a randomized, controlled, prospective study. One hundred patients with acute anterior wall ST-elevation myocardial infarction (STEMI) treated with acute PCI are randomized in a 1:1 way to either intracoronary transplantation of autologous mBMC 5-8 days after PCI or to control. Left ventricular function, exercise capacity, biochemical status, functional class, quality of life and complications are validated at baseline and during a 12-month follow up.
|Condition or disease||Intervention/treatment||Phase|
|Acute Anterior Wall Myocardial Infarction||Genetic: Intracoronary aotologous stem cell transplantation||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Autologous Stem Cell Transplantation in Acute Myocardial Infarction|
|Study Start Date :||September 2003|
|Study Completion Date :||May 2006|
- whether intracoronary mBMC transplantation improve LVEF after AMI assessed by ECG-gated SPECT.
- To test whether mBMC treatment improve exercise capacity assessed by bicycle ergometry
- To test whether mBMC treatment improve quality of life assessed by the SF 36 formula
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00199823
|Oslo, Norway, 0027|
|Principal Investigator:||Ketil Lunde, MD||Oslo University Hospital|